{"id":691152,"date":"2022-10-03T08:10:44","date_gmt":"2022-10-03T12:10:44","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-host-virtual-rd-event-on-non-tuberculous-mycobacterial-pulmonary-disease-and-the-spr720-program\/"},"modified":"2022-10-03T08:10:44","modified_gmt":"2022-10-03T12:10:44","slug":"spero-therapeutics-to-host-virtual-rd-event-on-non-tuberculous-mycobacterial-pulmonary-disease-and-the-spr720-program","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-host-virtual-rd-event-on-non-tuberculous-mycobacterial-pulmonary-disease-and-the-spr720-program\/","title":{"rendered":"Spero Therapeutics to Host Virtual R&D Event on Non-Tuberculous Mycobacterial Pulmonary Disease and the SPR720 Program"},"content":{"rendered":"
\n

\n Event is taking place on Thursday, October 6<\/em>
\n
\n th<\/em>
\n <\/sup>
\n at 11:30 a.m. ET<\/em>
\n \n <\/p>\n

\n Event will feature a presentation by key opinion leader, Kevin L. Winthrop, MD, MPH (Division of Infectious Disease, OHSU Medical School)<\/em>\n <\/p>\n

CAMBRIDGE, Mass., Oct. 03, 2022 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc.\u00a0(Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will host a virtual R&D event on Thursday, October 6, 2022, at 11:30 a.m. Eastern Time.<\/p>\n

The virtual event will feature a presentation by key opinion leader, Kevin L. Winthrop, MD, MPH, from the Division of Infectious Disease, OHSU Medical School.\u00a0\u00a0 During his presentation, Dr. Winthrop will discuss the etiology, unmet medical need, and treatment landscape of non-tuberculous mycobacteria (NTM) pulmonary disease. Members of the Spero management team will provide an overview of the development program for SPR720, a potential novel first line oral therapy for NTM infections.<\/p>\n

A live Q&A session will follow the formal presentations. To register for the event, please click here<\/a>.<\/p>\n

\n Dr. Winthrop Biography:<\/strong>\n <\/p>\n

Kevin L. Winthrop, MD, MPH, Professor of Public Health, Infectious Diseases, and Ophthalmology at Oregon Health and Science University, is a former staff infectious disease epidemiologist from the U.S. Centers for Disease Control and Prevention\u2019s Division of Tuberculosis Elimination. He has co-authored over 300 publications, many detailing the epidemiologic and clinical aspects of nontuberculous mycobacterial diseases, tuberculosis, and other infections associated with rheumatic diseases and biologic immunosuppressive therapies. Clinically, he provides regional consultations for mycobacterial diseases and other chronic chest infections and serves as the medical consultant to the Oregon Public Health Division\u2019s TB control program. His Center for Infectious Disease Studies has served as the lead institution and coordinating center for multiple cohort studies and clinical trials. He has served as a primary or senior investigator in many of these clinical and epidemiologic studies, and frequently collaborates with the Pulmonary Department on studies related to bronchiectasis. He founded the NTM Research Consortium and associated Clinical Trials Network which facilitate collaborative, multi-site grants and clinical trials among patients with NTM. He is a member of the graduate faculty at OHSU where he mentors public health students, medical students, and physicians in post-graduate training.<\/p>\n

\n About\u00a0Spero<\/strong>\u00a0Therapeutics<\/strong>
Spero Therapeutics, headquartered in Cambridge, Massachusetts,\u00a0is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing novel treatments for bacterial infections, including multi-drug resistant bacterial infections and rare diseases.<\/p>\n